Cardio Diagnostics Holdings, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Cardio Diagnostics Holdings, Inc. (CDIO) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $123.58 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-07
- Cardio Diagnostics Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $62.13K, a 5.93% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $61.45K, a 5.92% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $60.77K, a 5.92% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $59.84K, a 5.94% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $237.27K, a 5.96% increase from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $223.93K, a 4423.82% increase from fiscal 2023.
- Cardio Diagnostics Holdings, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $4.95K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $62.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $123.58K 10-Q · filed 2026-08-07 | $184.35K derived: sum of 3 quarters · filed 2026-08-07 | $244.18K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $61.45K 10-Q · filed 2026-05-15 | $122.21K derived: sum of 2 quarters · filed 2026-05-15 | $182.05K derived: sum of 3 quarters · filed 2026-05-15 | $240.71K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $60.77K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $120.60K derived: sum of 2 quarters · filed 2026-03-13 | $179.26K derived: sum of 3 quarters · filed 2026-08-07 | $237.27K 10-K · filed 2026-03-13 |
| 2025-09-30 | $59.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $118.49K derived: sum of 2 quarters · filed 2026-08-07 | $176.50K 10-Q · filed 2025-11-12 | $233.87K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $58.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $116.67K 10-Q · filed 2026-08-07 | $174.03K derived: sum of 3 quarters · filed 2026-08-07 | $230.51K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $58.01K 10-Q · filed 2026-05-15 | $115.38K derived: sum of 2 quarters · filed 2026-05-15 | $171.86K derived: sum of 3 quarters · filed 2026-05-15 | $227.20K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $57.37K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $113.85K derived: sum of 2 quarters · filed 2026-03-13 | $169.19K derived: sum of 3 quarters · filed 2026-03-13 | $223.93K 10-K · filed 2026-03-13 |
| 2024-09-30 | $56.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $111.83K derived: sum of 2 quarters · filed 2025-11-12 | $166.56K 10-Q · filed 2025-11-12 | $164.95K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $55.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $110.08K 10-Q · filed 2025-08-14 | $108.47K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $54.73K 10-Q · filed 2025-05-15 | $53.13K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | -$1.61K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $4.95K 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $6.56K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |